Which has better earnings & valuation, NDRA or BEAT?

ENDRA Life Sciences is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio ENDRA Life Sciences N/A N/A -$7.03M -$6.38 N/A HeartBeam N/A N/A -$21.01M -$0.51 N/A

Is NDRA or BEAT more profitable?

ENDRA Life Sciences' return on equity of -246.34% beat HeartBeam's return on equity. Company Net Margins Return on Equity Return on Assets ENDRA Life Sciences N/A -246.34% -150.81% HeartBeam N/A -686.78% -348.65%

Do analysts recommend NDRA or PETV?

ENDRA Life Sciences presently has a consensus target price of $25.00, suggesting a potential upside of 340.14%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe ENDRA Life Sciences is more favorable than PetVivo. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ENDRA Life Sciences 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 PetVivo 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Is NDRA or PETV more profitable?

ENDRA Life Sciences has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. ENDRA Life Sciences' return on equity of -246.34% beat PetVivo's return on equity. Company Net Margins Return on Equity Return on Assets ENDRA Life Sciences N/A -246.34% -150.81% PetVivo -902.82% -4,813.07% -281.78%

Is FEMY or NDRA more profitable?

ENDRA Life Sciences has a net margin of 0.00% compared to Femasys' net margin of -534.36%. Femasys' return on equity of -225.97% beat ENDRA Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Femasys -534.36% -225.97% -74.68% ENDRA Life Sciences N/A -246.34% -150.81%

ENDRA Life Sciences (NDRA) Competitors

$5.68 -0.78 (-12.07%)

As of 09/3/2026 04:00 PM Eastern

Compare

NDRA vs. BEAT, PETV, FEMY, CTSO, and LFWD

Should you buy ENDRA Life Sciences stock or one of its competitors? ENDRA Life Sciences's main competitors and comparable companies include HeartBeam (BEAT), PetVivo (PETV), Femasys (FEMY), Cytosorbents (CTSO), and Lifeward (LFWD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare equipment" industry.

How does ENDRA Life Sciences compare to HeartBeam?

ENDRA Life Sciences (NASDAQ:NDRA) and HeartBeam (NASDAQ:BEAT) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, dividends, earnings, profitability, risk and valuation.

In the previous week, ENDRA Life Sciences' average media sentiment score of 0.00 equaled HeartBeam'saverage media sentiment score.

Company	Overall Sentiment
ENDRA Life Sciences	Neutral
HeartBeam	Neutral

ENDRA Life Sciences currently has a consensus price target of $25.00, suggesting a potential upside of 340.14%. HeartBeam has a consensus price target of $4.00, suggesting a potential upside of 852.15%. Given HeartBeam's stronger consensus rating and higher probable upside, analysts plainly believe HeartBeam is more favorable than ENDRA Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
HeartBeam	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.67

1.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 7.8% of HeartBeam shares are held by institutional investors. 10.0% of ENDRA Life Sciences shares are held by insiders. Comparatively, 18.0% of HeartBeam shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ENDRA Life Sciences is trading at a lower price-to-earnings ratio than HeartBeam, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$6.38	N/A
HeartBeam	N/A	N/A	-$21.01M	-$0.51	N/A

ENDRA Life Sciences has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market. Comparatively, HeartBeam has a beta of -0.8, suggesting that its share price is 180% less volatile than the broader market.

ENDRA Life Sciences' return on equity of -246.34% beat HeartBeam's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-246.34%	-150.81%
HeartBeam	N/A	-686.78%	-348.65%

Summary

HeartBeam beats ENDRA Life Sciences on 8 of the 12 factors compared between the two stocks.

How does ENDRA Life Sciences compare to PetVivo?

ENDRA Life Sciences (NASDAQ:NDRA) and PetVivo (NASDAQ:PETV) are both small-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, analyst recommendations, valuation, media sentiment, profitability, earnings and risk.

ENDRA Life Sciences has a net margin of 0.00% compared to PetVivo's net margin of -902.82%. ENDRA Life Sciences' return on equity of -246.34% beat PetVivo's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ENDRA Life Sciences	N/A	-246.34%	-150.81%
PetVivo	-902.82%	-4,813.07%	-281.78%

ENDRA Life Sciences has higher earnings, but lower revenue than PetVivo. PetVivo is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$6.38	N/A
PetVivo	$1.05M	24.53	-$10.95M	-$0.34	N/A

1.2% of ENDRA Life Sciences shares are held by institutional investors. Comparatively, 24.5% of PetVivo shares are held by institutional investors. 10.0% of ENDRA Life Sciences shares are held by company insiders. Comparatively, 10.8% of PetVivo shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, PetVivo had 1 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 1 mentions for PetVivo and 0 mentions for ENDRA Life Sciences. ENDRA Life Sciences' average media sentiment score of 0.00 equaled PetVivo'saverage media sentiment score.

Company	Overall Sentiment
ENDRA Life Sciences	Neutral
PetVivo	Neutral

ENDRA Life Sciences presently has a consensus target price of $25.00, suggesting a potential upside of 340.14%. Given ENDRA Life Sciences' stronger consensus rating and higher possible upside, equities research analysts plainly believe ENDRA Life Sciences is more favorable than PetVivo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PetVivo	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

ENDRA Life Sciences has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market. Comparatively, PetVivo has a beta of 1.36, suggesting that its share price is 36% more volatile than the broader market.

Summary

ENDRA Life Sciences beats PetVivo on 8 of the 14 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Femasys?

Femasys (NASDAQ:FEMY) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, media sentiment, risk, valuation and institutional ownership.

Femasys has a beta of -2.07, indicating that its stock price is 307% less volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.05, indicating that its stock price is 105% less volatile than the broader market.

ENDRA Life Sciences has lower revenue, but higher earnings than Femasys. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Femasys, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Femasys	$2.29M	11.20	-$18.63M	-$3.53	N/A
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$6.38	N/A

ENDRA Life Sciences has a net margin of 0.00% compared to Femasys' net margin of -534.36%. Femasys' return on equity of -225.97% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Femasys	-534.36%	-225.97%	-74.68%
ENDRA Life Sciences	N/A	-246.34%	-150.81%

65.3% of Femasys shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 7.8% of Femasys shares are owned by insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

In the previous week, Femasys' average media sentiment score of 0.00 equaled ENDRA Life Sciences'average media sentiment score.

Company	Overall Sentiment
Femasys	Neutral
ENDRA Life Sciences	Neutral

Femasys currently has a consensus target price of $50.00, indicating a potential upside of 1,533.99%. ENDRA Life Sciences has a consensus target price of $25.00, indicating a potential upside of 340.14%. Given Femasys' stronger consensus rating and higher probable upside, equities analysts clearly believe Femasys is more favorable than ENDRA Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Femasys	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Femasys beats ENDRA Life Sciences on 9 of the 13 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Cytosorbents?

Cytosorbents (NASDAQ:CTSO) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

ENDRA Life Sciences has a net margin of 0.00% compared to Cytosorbents' net margin of -48.94%. ENDRA Life Sciences' return on equity of -246.34% beat Cytosorbents' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Cytosorbents	-48.94%	-431.65%	-41.94%
ENDRA Life Sciences	N/A	-246.34%	-150.81%

Cytosorbents currently has a consensus target price of $5.38, suggesting a potential upside of 1,435.71%. ENDRA Life Sciences has a consensus target price of $25.00, suggesting a potential upside of 340.14%. Given Cytosorbents' higher probable upside, equities analysts plainly believe Cytosorbents is more favorable than ENDRA Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Cytosorbents	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

32.9% of Cytosorbents shares are held by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are held by institutional investors. 7.8% of Cytosorbents shares are held by company insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Cytosorbents has a beta of 1.34, suggesting that its share price is 34% more volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market.

In the previous week, Cytosorbents had 6 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 6 mentions for Cytosorbents and 0 mentions for ENDRA Life Sciences. ENDRA Life Sciences' average media sentiment score of 0.00 beat Cytosorbents' score of -0.10 indicating that ENDRA Life Sciences is being referred to more favorably in the news media.

Company	Overall Sentiment
Cytosorbents	Neutral
ENDRA Life Sciences	Neutral

ENDRA Life Sciences has lower revenue, but higher earnings than Cytosorbents. Cytosorbents is trading at a lower price-to-earnings ratio than ENDRA Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Cytosorbents	$37.06M	0.59	-$8.20M	-$0.29	N/A
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$6.38	N/A

Summary

Cytosorbents beats ENDRA Life Sciences on 7 of the 13 factors compared between the two stocks.

How does ENDRA Life Sciences compare to Lifeward?

Lifeward (NASDAQ:LFWD) and ENDRA Life Sciences (NASDAQ:NDRA) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, media sentiment, valuation, risk, dividends and analyst recommendations.

ENDRA Life Sciences has a net margin of 0.00% compared to Lifeward's net margin of -141.28%. Lifeward's return on equity of -235.86% beat ENDRA Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lifeward	-141.28%	-235.86%	-81.72%
ENDRA Life Sciences	N/A	-246.34%	-150.81%

Lifeward has a beta of 0.39, suggesting that its share price is 61% less volatile than the broader market. Comparatively, ENDRA Life Sciences has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market.

In the previous week, Lifeward had 4 more articles in the media than ENDRA Life Sciences. MarketBeat recorded 4 mentions for Lifeward and 0 mentions for ENDRA Life Sciences. Lifeward's average media sentiment score of 0.10 beat ENDRA Life Sciences' score of 0.00 indicating that Lifeward is being referred to more favorably in the media.

Company	Overall Sentiment
Lifeward	Neutral
ENDRA Life Sciences	Neutral

26.8% of Lifeward shares are owned by institutional investors. Comparatively, 1.2% of ENDRA Life Sciences shares are owned by institutional investors. 1.5% of Lifeward shares are owned by company insiders. Comparatively, 10.0% of ENDRA Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ENDRA Life Sciences has lower revenue, but higher earnings than Lifeward. ENDRA Life Sciences is trading at a lower price-to-earnings ratio than Lifeward, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lifeward	$22.03M	0.91	-$19.91M	-$16.82	N/A
ENDRA Life Sciences	N/A	N/A	-$7.03M	-$6.38	N/A

Lifeward currently has a consensus price target of $10.00, suggesting a potential upside of 40.85%. ENDRA Life Sciences has a consensus price target of $25.00, suggesting a potential upside of 340.14%. Given ENDRA Life Sciences' higher possible upside, analysts plainly believe ENDRA Life Sciences is more favorable than Lifeward.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lifeward	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
ENDRA Life Sciences	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Lifeward beats ENDRA Life Sciences on 10 of the 15 factors compared between the two stocks.

Get ENDRA Life Sciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NDRA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

NDRA vs. The Competition

Export

Metric	ENDRA Life Sciences	Healthcare Equipment & Supplies Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$9.69M	$5.81B	$7.26B	$12.73B
Dividend Yield	N/A	1.76%	2.53%	8.86%
P/E Ratio	-0.89	25.92	273.29	25.25
Price / Sales	N/A	73.24	621.79	97.64
Price / Cash	N/A	33.14	77.82	52.26
Price / Book	1.35	6.04	13.08	6.14
Net Income	-$7.03M	$150.03M	$3.47B	$349.01M
7 Day Performance	13.37%	-1.38%	0.52%	-0.31%
1 Month Performance	34.60%	1.21%	5.63%	0.64%
1 Year Performance	33.33%	9.83%	25.31%	14.83%

ENDRA Life Sciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
NDRA ENDRA Life Sciences	2.169 of 5 stars	$5.68 -12.1%	$25.00 +340.1%	+29.4%	$9.69M	N/A	N/A	20	Positive News
BEAT HeartBeam	1.8006 of 5 stars	$0.50 +4.1%	$4.00 +695.2%	-70.2%	$27.23M	N/A	N/A	1,700
PETV PetVivo	N/A	$0.68 -2.5%	N/A	-15.5%	$25.81M	$1.05M	N/A	20	News Coverage Gap Down
FEMY Femasys	2.915 of 5 stars	$2.85 -4.4%	$50.00 +1,654.4%	-58.6%	$24.96M	$2.29M	N/A	30
CTSO Cytosorbents	2.0863 of 5 stars	$0.36 -4.0%	$5.38 +1,412.8%	-64.3%	$23.26M	$37.06M	N/A	220	News Coverage Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:NDRA) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ENDRA Life Sciences (NDRA) Competitors

NDRA vs. BEAT, PETV, FEMY, CTSO, and LFWD

How does ENDRA Life Sciences compare to HeartBeam?

Summary

How does ENDRA Life Sciences compare to PetVivo?

Summary

How does ENDRA Life Sciences compare to Femasys?

Summary

How does ENDRA Life Sciences compare to Cytosorbents?

Summary

How does ENDRA Life Sciences compare to Lifeward?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NDRA vs. The Competition

ENDRA Life Sciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ENDRA Life Sciences (NDRA) Competitors

NDRA vs. BEAT, PETV, FEMY, CTSO, and LFWD

How does ENDRA Life Sciences compare to HeartBeam?

Does the media prefer NDRA or BEAT?

Do analysts recommend NDRA or BEAT?

Do insiders & institutionals believe in NDRA or BEAT?

Which has better earnings & valuation, NDRA or BEAT?

Which has more volatility & risk, NDRA or BEAT?

Is NDRA or BEAT more profitable?

Summary

How does ENDRA Life Sciences compare to PetVivo?

Is NDRA or PETV more profitable?

Which has higher earnings and valuation, NDRA or PETV?

Do insiders and institutionals believe in NDRA or PETV?

Does the media prefer NDRA or PETV?

Do analysts recommend NDRA or PETV?

Which has more volatility and risk, NDRA or PETV?

Summary

How does ENDRA Life Sciences compare to Femasys?

Which has more volatility and risk, FEMY or NDRA?

Which has better earnings and valuation, FEMY or NDRA?

Is FEMY or NDRA more profitable?

Do institutionals and insiders believe in FEMY or NDRA?

Does the media favor FEMY or NDRA?

Do analysts rate FEMY or NDRA?

Summary

How does ENDRA Life Sciences compare to Cytosorbents?

Is CTSO or NDRA more profitable?

Do analysts prefer CTSO or NDRA?

Do institutionals & insiders hold more shares of CTSO or NDRA?

Which has more volatility and risk, CTSO or NDRA?

Does the media favor CTSO or NDRA?

Which has higher earnings & valuation, CTSO or NDRA?

Summary

How does ENDRA Life Sciences compare to Lifeward?

Is LFWD or NDRA more profitable?

Which has more volatility and risk, LFWD or NDRA?

Does the media favor LFWD or NDRA?

Do institutionals and insiders hold more shares of LFWD or NDRA?

Which has stronger valuation and earnings, LFWD or NDRA?

Do analysts recommend LFWD or NDRA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

NDRA vs. The Competition

ENDRA Life Sciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools